Fig. In vivo efficacy of anti-PD-1/CTLA-4 antibody drugs in inhibiting MC38 and CT26 colorectal cancer xenografts.
Fig. Mouse Lewis lung cancer pleural effusion model constructed by in situ injection of LLC-Luc cell line. a. Efficacy tumourigenic curve; b. Efficacy body weight curve; c. Survival rate of mice; d. Photographs of lungs, tumours, and pleural effusions in mice.
Fig. In vivo efficacy of ADC drugs targeting NECTN4 to inhibit the progression of MC38-NECTIN4 homologous tumour cells (host is hPD-1 mice on C57BL6 background)
Fig. Evaluation of antitumour efficacy in hTNFR2 humanised mice. a. Efficacy tumourigenic curve; b. Efficacy body weight curve.
Fig. Evaluation of antitumour efficacy in hPD1/hCTLA4 humanised mice. a. Efficacy tumourigenic curve; b. Efficacy body weight curve.
